MPM Tests Regenecare(TM) For Cancer Drug Rash.

IRVING, Texas -- MPM Medical, Inc., a wholly owned subsidiary of RBC Life Sciences, Inc. (OTCBB:RBCL), announced the initiation of human clinical trials, in three medical institutions, designed to evaluate the efficacy of its topical wound gel, Regenecare[TM], in the relief of painful, itching skin rashes that occur as a side effect during treatment by a group of widely-used cancer drugs known as epidermal growth factor receptor (EGFR) inhibitors.

EGFR drugs are marketed by several pharmaceutical companies under various trade names. They are used to treat cancers of the head, neck, gastric tract, lungs and pancreas. However, within a few weeks of use, a majority of patients develop painful, itching, red skin rashes on the face, chest, and back. A number of physicians reported to MPM that when they applied Regenecare to the rash areas three to four times per day, the side effects of EGFR drugs were significantly reduced. Based on these physician reports, MPM is sponsoring the double-blind human clinical trials, results of which are expected to be submitted for publication in peer reviewed journals later this year.

Paul Miller, President of MPM said, "Preliminary results in one 20 patient study has shown statistically significant reduction of pain and itching after applying Regenecare to the rash area. These results were presented last week in California at the Ninth National Research Conference of the Oncology Nurses Society."

MPM Medical, Inc. develops and markets a proprietary line of research-based wound care products.

The statements above, other than statements of historical facts, may be forward-looking. Actual events will be dependent upon a number of factors and risks including but not limited to changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.